Predict your next investment

HEALTHCARE | Biotechnology

See what CB Insights has to offer

Stage

Grant | Alive

Total Raised

$10K

Last Raised

$10K | 3 yrs ago

About GlyCa BioSciences

GlyCa BioSciences has a technology that uses sugar as a cancer biomarker, which together with tissue-specific markers, can detect and/or predict high-risk prostate cancer with a simple blood test.

GlyCa BioSciences Headquarter Location

Alberta,

Canada

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing GlyCa BioSciences

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

GlyCa BioSciences is included in 1 Expert Collection, including Cancer.

C

Cancer

3,605 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.

GlyCa BioSciences Patents

GlyCa BioSciences has filed 1 patent.

The 3 most popular patent topics include:

  • Gastrointestinal cancer
  • Infectious causes of cancer
  • Inflammations
patents chart

Application Date

Grant Date

Title

Related Topics

Status

5/8/2018

Infectious causes of cancer, Oncology, Oral mucosal pathology, Gastrointestinal cancer, Inflammations

Application

Application Date

5/8/2018

Grant Date

Title

Related Topics

Infectious causes of cancer, Oncology, Oral mucosal pathology, Gastrointestinal cancer, Inflammations

Status

Application

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.